These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39377592)

  • 1. Evaluation of the safety of PD-1/PD-L1 inhibitors for immunotherapy in patients with malignant tumors after COVID-19 infection: A single-center cohort study.
    Liao K; Cheng J; Hu Y; Zhang B; Huang P; Liu J; Zhang W; Hu H; Bai X; Qian Y; Guo D; Ai K; Zhu Y; Huang L
    Cancer Med; 2024 Oct; 13(19):e70202. PubMed ID: 39377592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
    Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical predictive value of PD-1/PD-L1-induced electrocardiogram changes for cardiotoxicity].
    Xue N; Peng LL; Wu DW; Li XJ
    Zhonghua Zhong Liu Za Zhi; 2024 Oct; 46(10):979-986. PubMed ID: 39414599
    [No Abstract]   [Full Text] [Related]  

  • 9. Steven-Johnson Syndrome/Toxic Epidermal Necrolysis is Associated with PD-1/PD-L1 Inhibitors Usage: A Case Series.
    Cao R; Xu T
    Br J Hosp Med (Lond); 2024 Sep; 85(9):1-11. PubMed ID: 39347662
    [No Abstract]   [Full Text] [Related]  

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
    Patrinely JR; Young AC; Quach H; Williams GR; Ye F; Fan R; Horn L; Beckermann KE; Gillaspie EA; Sosman JA; Friedman DL; Moslehi JJ; Johnson DB
    Eur J Cancer; 2020 Aug; 135():211-220. PubMed ID: 32599411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a Nationwide Inpatient Database.
    Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
    Clin Lung Cancer; 2024 Sep; 25(6):e243-e251. PubMed ID: 38909011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study on the efficacy and tolerability of dose modification of PD-1 and PD-L1 inhibitors in hospital-system community outpatient cancer clinics.
    Allen E; Brown EN; Torre R; Murthy A
    J Oncol Pharm Pract; 2024 Apr; 30(3):507-512. PubMed ID: 37218160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
    Bitton K; Michot JM; Barreau E; Lambotte O; Haigh O; Marabelle A; Voisin AL; Mateus C; Rémond AL; Couret C; Champiat S; Labetoulle M; Rousseau A
    Am J Ophthalmol; 2019 Jun; 202():109-117. PubMed ID: 30772350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
    Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis.
    Leppelmann KS; Mooradian MJ; Ganguli S; Uppot RN; Yamada K; Irani Z; Wehrenberg-Klee EP; Zubiri L; Reynolds KL; Arellano RS; Hirsch JA; Sullivan RJ; Fintelmann FJ
    J Vasc Interv Radiol; 2021 Feb; 32(2):187-195. PubMed ID: 33353814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
    Yoon JH; Hong AR; Kim HK; Kang HC
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.